AU Patent

AU2024204928B2 — Use of cannabidiols in the treatment of epilepsy

Assigned to Jazz Pharmaceuticals Research UK Ltd · Expires 2026-02-12 · 0y expired

What this patent protects

1005374872 The present disclosure relates to the use of cannabidiol (CBD) in the treatment of absence seizures. In particular, the disclosure relates to the use of CBD for reducing absence seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuber…

USPTO Abstract

1005374872 The present disclosure relates to the use of cannabidiol (CBD) in the treatment of absence seizures. In particular, the disclosure relates to the use of CBD for reducing absence seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; CDKL5; Dup15q; Jeavons syndrome; Myoclonic 5 Absence Epilepsy; Neuronal ceroid lipofuscinoses (NCL) and brain abnormalities. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs). 10

Drugs covered by this patent

Patent Metadata

Patent number
AU2024204928B2
Jurisdiction
AU
Classification
—
Expires
2026-02-12
Drug substance claim
No
Drug product claim
No
Assignee
Jazz Pharmaceuticals Research UK Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.